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Abstract: The relationship between higher variant allele fraction (VAF) of genomic alterations in circulating tumor
DNA (%ctDNA), an indicator of poor outcome, and maximum standardized uptake value (SUVmax), the most commonly used semi-quantitative parameter in 18F-FDG PET/CT, has not been studied. Overall, 433 cancer patients had
blood-based next generation sequencing. Maximum and sum of %ctDNA alterations (%ctDNAmax and %ctDNAsum,
respectively) represent the maximum and sum of VAF, reported as a percentage. The subset of 46 eligible patients
had treatment-naïve metastatic disease and PET/CT imaging, with median 13 days prior to ctDNA testing. We found
a linear correlation between the maximum VAF (%ctDNAmax) (as well as the sum of the VAFs (%ctDNAsum)) and SUVmax
of the most 18F-FDG-avid lesion (r=0.43, P=0.003; r=0.43, P=0.002; respectively). Our data suggest that SUVmax may
be a non-invasive and readily available surrogate indicator for %ctDNA, a prognostic factor for patient survival. Since
higher %ctDNA has been previously correlated with worse outcome, the relationship between SUVmax, %ctDNA and
survival warrants further study.
Keywords: Genomic alterations, circulating tumor DNA (ctDNA), Variant allele fraction of genomic alterations in
circulating tumor DNA (%ctDNA), SUVmax, cancer, PET/CT

Introduction
PET/CT with 18F-FDG is commonly performed in
the initial staging and subsequent evaluation of
patients with cancer. With recent advances in
genomic data acquisition, exploring correlations between imaging and genomic alterations
is of interest, as there is the possibility that
imaging can ultimately serve as a non-invasive
and readily available surrogate for molecular
features [1, 2].
Genomic alterations are the hallmark of cancer
and can be used to predict survival by acting as
prognostic or predictive biomarkers [3, 4].
Genomic abnormalities can be deduced from
interrogation of either tissue biopsy or the socalled liquid biopsy. A liquid biopsy is obtained
from fluids such as blood plasma that contains
circulating tumor cells (CTCs) or circulating cell-

free DNA fragments, designated as circulating
tumor DNA (ctDNA), as well as exosomes (EXOs),
namely membrane-encapsulated subcellular
structures containing proteins and nucleic
acids shed from tumor cells into the bloodstream [5, 6]. Liquid biopsies are increasingly
being leveraged in the clinical setting because,
compared to tissue biopsy, they are non-invasive, faster, and associated with less technical
difficulty and morbidity [7]. If there is a contraindication to an invasive tissue biopsy or the tissue sample is inadequate, liquid biopsies may
be the only choice for genomic evaluation [8]. It
was recently shown that higher variant allele
fractions (VAFs) (also known as percent circulating tumor DNA (%ctDNA)) for genomic alterations in liquid biopsies correlate with shorter
patient survival [9-11]. Higher total number of
alterations in ctDNA may also be an indicator of
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more aggressive tumor biology and poorer survival [12].

Materials and methods

same GE Discovery VCT scanner (Waukesha,
WI) for all the patients, following an uptake period of one hour in a quiet room at rest. Wholebody CT was performed from the region of the
head to the mid-thigh or toes. PET imaging was
performed, in the 3D acquisition mode, at a
rate of 2 minutes/bed position, after the CT
scan. CT images were reconstructed onto a
512×512 matrix. With a standard whole-body
3D iterative reconstruction, PET images were
reconstructed using: 2 iterations; 28 subsets
onto a 128×128 matrix with decay correction,
attenuation correction, and scatter correction.
The photon energy window was standard at
425-650 keV. The reconstruction diameter was
70 cm, the slice thickness was 3.27 mm, the
pixel size was 5.47 mm×5.47 mm, and the spatial resolution was 5 mm.

Patient selection

Image analysis

We interrogated our database of 433 consecutive eligible patients with cancer, at University
of California San Diego Moores Center for
Personalized Cancer Therapy, for whom NGS
(ctDNA and tissue DNA) had been performed
(June 2014 to Sept 2017). Eligibility implied
patients meeting UCSD IRB guidelines for waiver or consent. This study was conducted in
accordance with the UCSD internal review
board (IRB)-approved protocol (NCT02478931)
[16]. Among these patients, we found 46 individuals with advanced cancers who had undergone 18F-FDG PET/CT within 64 days prior to
the blood draw (to ensure acceptable temporal
correlation between imaging and genomic evaluation) and had no history of prior systemic
treatment. Data were abstracted from the electronic medical record.

PET images were interpreted by a nuclear medicine physician and verified by a second nuclear
medicine physician, on the pictures archiving
and communication system (PACS), (AGFA
Impax 6.3, Mortsel Belgium). SUV of the most
18
F-FDG-avid lesion, larger than 1 cm, was
obtained by manually placing a circular region
of interest (ROI) at the site of the maximum 18FFDG uptake and the maximal activity (SUVmax)
was recorded. We calculated SUV as decaycorrected activity of tissue volume (kBq/mL)/
injected 18F-FDG activity per body mass (kBq/g).
For 2 patients without elevated focal 18F-FDG
uptake on PET, a rounded SUVmax of 0 was
recorded.

Maximum standardized uptake value (SUVmax)
is the most commonly used semiquantitative
measurement, for the semi-quantification of
FDG PET in a region of interest. It is the most
robust, reliable, accurate and reproducible
value for assessment of treatment response in
cancer patients [13]. We recently demonstrated that SUVmax is related to the tumor mutational burden (TMB) and total number of oncogenic
anomalies in the tissue biopsy [14, 15]. In this
study, we sought to evaluate the relationship
between SUVmax and the %ctDNA of genomic
alterations in liquid biopsies.

18

F-FDG PET-CT imaging

Patients had 18F-FDG PET-CT imaging as needed routinely, for their disease assessment, and
follow-up. Fasting for at least six hours prior to
the scan,was a standard part of the imaging
protocol. Immediately before the 18F-FDG injection, blood glucose levels were measured and
no patient had a blood glucose level >160 mg/
dl, to avoid inaccurate semiquantitative SUVmax
and need for glucose correction [17]. Within 10
seconds, patients were injected with 370-740
MBq 18F-FDG, intravenously. Multi-station
3-dimensional (3D) whole body PET acquisition
with CT was performed for ~60 min, using the
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Sequencing
Guardant Health, Inc. (Redwood City, CA), a
Clinical Laboratory Improvement Amendment
(CLIA)-certified and College of American
Pathologists (CAP)-accredited clinical laboratory, performed digital Sequencing of ctDNA. The
analytical and clinical validation of Guardant
360 was conducted in conformance with standards established by Evaluation of Genomic
Applications in Practice and Prevention (EGAPP), the Standards for Reporting of Diagnostic
Accuracy (STARD), REporting of tumor MARKer
Studies (REMARK), and the recent Nextgeneration Sequencing: Standardization of
Clinical Testing (Nex-StoCT) biomarker guidelines [18]. We isolated 5-30 ng of ctDNA from
plasma, using two 10 mL Streck tubes drawn
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Table 1. Patient characteristics
SUVmax (Mean ± SD)
6.97±4.56
Median (range)
6 (0-23)
Days between PET & blood draw (Mean ± SD) 18.2±16.7
Median (range)
13 (1-64)
%ctDNAsum (Mean ± SD)
7.25±12.1
Median (range)
1.15 (0-43.5)
%ctDNAmax (Mean ± SD)
(Mean ± SD)
5.16±9.28
Median (range)
0.85 (0-43.5)
Age at time of biopsy (years) (Mean ± SD)
58.3±12.5
Median (range)
59.5 (34-81)
Women (N (%))
30 (65.2%)
Men (N (%))
16 (34.7%)
Lung cancer (N (%))
19 (41%)
Gastrointestinal cancer (N (%))
8 (17%)
Breast cancer (N (%))
6 (13%)
Brain cancer (N (%))
5 (10%)
Head and neck cancer (N (%))
5 (10%)
Other cancers (N (%))
3 (6%)
Abbreviations: ctDNA = circulating tumor DNA; SD = standard deviation.

from each patient. Sequencing libraries were
made with custom in-line barcode molecular
tagging, and 15,000× read depth complete
sequencing. The current panel uses hybrid capture and subsequent NGS of critical exons in a
panel of 70 genes. It reports all four major
types of genomic alterations (indels, point
mutations, fusions, and copy-number amplifications). To remove false positive results, postsequencing bioinformatics matches the complementary strands of each barcoded DNA
fragment [18]. VAF represents %ctDNA alteration reported as percentage and computed as
the number of mutated DNA molecules divided
by the total number (mutated plus wild-type) of
DNA fragments at that allele. Most of the cellfree DNA is wild-type (germline); therefore, the
median VAF of somatic alterations is <0.5%.
ctDNAsum was defined as sum of individual alterations in the ctDNA, not including variants of
unknown significance (VUS). ctDNAmax was
defined as maximum individual alteration in the
ctDNA, not including VUS.
Statistical analysis
Statistical analysis was performed using R, version 3.5.2. The diagnostics from the statistical
model indicated that SUVmax and %ctDNA alter309

ations should be analyzed on the logarithmic scale. We found that if we log-transform only one variable or neither of the
two variables, there were still outliers and
strongly influential points that made the
model a poor fit. However, in the logscale, there was no evidence, based on
the residual-vs.-leverage and residualsvs.-fitted plots of the log-scale data analysis, that any point was exerting undue
influence over the correlation, therefore
no data point was removed as an outlier.
Because there were multiple SUVmax,
%ctDNAmax, and %ctDNAsum with rounded
zero values, these values were first transformed to a shifted-log by adding 1 prior
to applying a base 10 logarithm to the values. The Pearson’������������������������
s correlation was determined from the regression of the shiftedlog SUVmax with the shifted-log %ctDNAmax,
and shifted-log %ctDNAsum.
Results
Patient characteristics
In our database of 433 patients with diverse
cancers and tissue and blood ctDNA NGS, we
found 46 patients with metastatic malignancies who had undergone 18F-FDG PET/CT within
64 days prior to their blood draw and were
treatment naïve in the metastatic setting.
Patients’ median age was 59.5 years (range:
34-81 years). There was a predominance of
women over men [n=30 (65.2%): n=16 (34.7%)].
The primary organ for the primary cancer was
lung (41%), followed by gastrointestinal (17%),
breast (13%), brain and head and neck (10%
each), and other (6%) (Table 1).
%ctDNA analysis
%ctDNAsum and %ctDNAmax are the sum of the
percentages of each deleterious ctDNA alteration and the maximum %ctDNA of any deleterious alteration, respectively; %ctDNA represents the VAF reported as a percentage.
Median time between the PET/CT and blood
draw was 13 days. Of the 46 patients evaluated, 34 (73.9%) had at least one ctDNA alteration. Mean ± standard deviation, median and
range of %ctDNAsum were 7.25±12.1, 1.15, and
0-43.5, respectively. Mean ± standard deviation, median and range of %ctDNAmax were
5.16±9.28, 0.85, and 0-43.5, respectively.
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Figure 1. log(SUVmax+1) is linearly correlated with
the log(%ctDNAsum+1) (r=0.43, P=0.002) using Pearson’s correlation. The graph represents the regression on the shifted-log scale. The circles represent
individual data points, N=46. Only deleterious alterations (no VUSs) are included in %ctDNA calculations.

Figure 2. log(SUVmax+1) is linearly correlated with
log(%ctDNAmax+1) (r=0.43, P=0.003) using Pearson’s correlation. The graph represents the regression on the shifted-log scale. The circles represent
individual data points, N=46. Only deleterious alterations (no VUSs) are included in %ctDNA calculations.

SUVmax correlates with %ctDNAsum and %ctDNAmax

[15]. Our hypothesis is that a higher burden of
ctDNA genomic alterations, as reflected by
%ctDNA, might correlate with higher SUVmax
with a similar rationale.

The Pearson correlation coefficient was r=0.43
(P=0.002) for the linear correlation between
the shifted-log sum of VAFs of genomic alterations in circulating tumor DNA (%ctDNAsum) and
shifted-log SUVmax (Figure 1). The Pearson correlation coefficient was r=0.43 (P=0.003) for
the linear correlation between the shifted-log
maximum VAF of genomic alterations in circulating tumor DNA (%ctDNAmax) and shifted-log
SUVmax (Figure 2).
Discussion
Here we present the PET imaging correlates of
genomic alterations in patients with diverse
metastatic cancers. Prior PET studies have
investigated the relationship between glucose
metabolic rate and tumor immune microenvironment and have shown an association
between metabolic and immune profiles [19,
20]. 18F-FDG PET imaging has been suggested
as a method to estimate tumor immune status
[21]. To our knowledge, this is the first report
which investigates the relationship between
SUVmax and %ctDNA of genomic alterations. We
previously demonstrated a significant positive
correlation between SUVmax and TMB, speculating metabolic reconfiguration and immune
inflammatory response as potential causes
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From 433 evaluated pan-cancer patients with
ctDNA data, only 46 passed stringent criteria to
be included in the study: (i) 18F-FDG PET/CT
within 64 days prior to the ctDNA blood draw;
(ii) no history of prior systemic treatment; and
(iii) advanced metastatic disease. These criteria ensured that the relationship between imaging and genomic data is not confounded by long
time lapse or treatment. Our study confirmed
that higher sum VAF of genomic alterations in
circulating tumor DNA, (%ctDNAsum), and higher
maximum VAF of genomic alterations in ctDNA
(%ctDNAmax), were both correlated with higher
SUVmax, with moderate correlation coefficient of
r=0.43 (P=0.002 and 0.003, respectively).
Consistent with these results, we have previously shown that higher SUVmax is found in
tumors with higher number of characterized
genomic alterations [22].
We hypothesize that a higher load of genomic
alterations, evidenced by higher sum and maximum VAF of genomic alterations in circulating
tumor DNA (%ctDNAmax, and %ctDNAsum) promote metabolic reconfiguration. This results in
increased glucose metabolism rate and a higher SUVmax. Although higher VAF could be due to
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higher mutational burden, resulting in metabolic reconfiguration, there are other possibilities
that require future study. For instance, higher
VAF could be due to larger tumor mass or due
to tumor shedding more ctDNA and/or being
more metabolically active. Alternatively, it is
conceivable that both SUVmax and %ctDNA
reflect tumor burden. An innate immune
response to tumors with higher VAFs, may be
an alternative explanation for the correlation
between ctDNA alterations and SUVmax. The
higher SUVmax (increased glycolytic activity) may
be due to an immune cell infiltrate from an
inflammatory response. Therefore, the exact
mechanism for the finding of correlation
between higher SUVmax and increased %ctDNA
is not understood.
There are several important limitations in our
study. First, %ctDNA and SUVmax parameters
are not fully synchronized due to the retrospective study design; therefore, prospective studies with same-day imaging and blood draw are
needed to validate our findings. Second, this
was a single-center study and only 46 patients
passed our stringent inclusion criteria even
though the full cohort include 433 patients;
thus, the sample size and number of centers in
the study need to be expanded. Third, the
underlying biochemical mechanism underlying
the relationship between %ctDNA alterations
and SUVmax is unknown and further studies are
needed to shed light on the mechanism. Fourth,
although higher %ctDNA has been demonstrate
to correlate with poor outcome in several studies [9-11], we speculate that higher SUVmax may
also be associated with a worse outcome [23],
but didn’t directly evaluate the prognostic
impact of SUVmax, which needs to be performed
to understand potential confounders in the
relationship between SUVmax and prognosis.
Thus, future larger prospective investigations
should address the aforementioned four limitations to understand the relationship between
SUVmax, %ctDNA, and patient survival are warranted. An important next study might be to
test SUVmax as an indicator of %ctDNA and vice
versa, and also to evaluate how effective each
of these parameters, are alone or in combination, as prognostic indicators, and whether or
not one can be a proxy for the other. In conclusion, we found a linear relationship between
SUVmax and %ctDNA of the genomic alterations
in the blood, assessed by next generation
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sequencing (NGS) of liquid biopsies. The relationship between SUVmax, %ctDNA and survival
warrants further study to test SUVmax as an
indicator of %ctDNA and vice versa, both being
potential prognostic indicators.
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